Variational AI releases Enki 4: Major update to foundation model for small- molecule drug discovery
Read More: Variational AI releases Enki 4: Major update to foundation model for small- molecule drug discoveryVariational AI introduces Enki™ 4: an improved algorithm and architecture designed to scale, expanding the pre-trained target coverage from 592 to 760 and now applicable to proximity-based therapeutics and novel payloads for antibody drug conjugates. Read More about Variational AI releases Enki 4: Major update to foundation model for small- molecule drug discovery
Our Latest News
Featured
Blog & Press
Variational AI releases Enki 4: Major update to foundation model for small- molecule drug discovery
Variational AI introduces Enki™ 4: an improved algorithm and architecture designed to scale, expanding the pre-trained target coverage from 592 to 760 and now applicable to proximity-based therapeutics and novel… Read More about Variational AI releases Enki 4: Major update to foundation model for small- molecule drug discovery
Enamine joins Variational AI in Agora Open-Science PRMT6 Discovery Effort
Variational AI is pleased to share that Enamine has joined the Agora Open Science Trust collaboration focused on discovering novel PRMT6 inhibitors for Spinal and Bulbar Muscular Atrophy (SBMA), a… Read More about Enamine joins Variational AI in Agora Open-Science PRMT6 Discovery Effort
Variational AI and Rakovina Therapeutics Expand Collaboration to Accelerate Next-Generation ATR Inhibitors
Variational AI and Rakovina Therapeutics expand their collaboration to advance Rakovina’s kt-5000 series of ATR inhibitors Read More about Variational AI and Rakovina Therapeutics Expand Collaboration to Accelerate Next-Generation ATR Inhibitors
Update: Advancing CNS-penetrant ATR inhibitors with Enki™
Building on their initial hit series, Variational AI and Rakovina Therapeutics share promising new results on ATR inhibitors generated with Enki. The latest findings reveal compounds that balance potency, selectivity,… Read More about Update: Advancing CNS-penetrant ATR inhibitors with Enki™
Variational AI Enters Collaboration with Merck to Apply Generative AI to Drug Discovery
Variational AI, a generative AI drug discovery company, announced a collaboration with Merck, known as MSD outside of the United States and Canada, to apply Variational AI’s Enki™ platform to… Read More about Variational AI Enters Collaboration with Merck to Apply Generative AI to Drug Discovery
Variational AI & Life Chemicals join forces to discover selective dual EGFR/FGFR1 inhibitors using generative AI
Following their successful 2022 collaboration, which targeted the SARS-CoV-2 main protease, Variational AI and Life Chemicals have partnered for a second time to discover de novo generated selective dual EGFR/FGFR1… Read More about Variational AI & Life Chemicals join forces to discover selective dual EGFR/FGFR1 inhibitors using generative AI
Upcoming Events
BostonVariational AI to Present at PBSS Event on AI and ML in Drug Discovery
Variational AI will participate in the upcoming Boston Pharmaceutical & Bioscience Society (PBSS) event, “Artificial Intelligence and Machine Learning: Shaping the Future of Therapeutic Drug Discovery, Development, and Manufacturing,” taking place April 28, 2026, in Cambridge, MA. This full-day symposium brings together leaders from biotechnology, academia, and pharmaceutical companies to discuss how artificial intelligence and
Learn More about Variational AI to Present at PBSS Event on AI and ML in Drug Discovery
VancouverVariational AI at WebSummit Vancouver 2026
Variational AI is joining Web Summit Vancouver 2026, one of the world’s premier technology conferences, bringing together over 20,000 attendees, investors, and innovators from across the globe, right here in Vancouver. Handol Kim, Co-Founder and Chief Executive Officer of Variational AI, and Valentin Beuchillot, Senior Manager of BD & Marketing, will both be on the
San DiegoVariational AI at BIO International Convention 2026
Variational AI will be attending BIO International Convention 2026 in San Diego. We’ll be onsite for partnering meetings to connect with pharma and biotech teams interested in accelerating small-molecule programs with generative AI—especially where speed, novelty, and multi-parameter optimization are key. Our delegation will include: Handol Kim, CEO Pete Guzzo, EVP & Head of Drug
Learn More about Variational AI at BIO International Convention 2026
MontrealVariational AI at CCG’s North American UGM & Conference 2026
Variational AI will be at the CCG North American UGM & Conference in Montreal (June 23–26, 2026). Join Alex Perryman’s scientific presentation on June 25 on how MOE supported multiple drug discovery programs.
Learn More about Variational AI at CCG’s North American UGM & Conference 2026
- Boston
Variational AI at Discovery on Target 2026
Variational AI will participate in Discovery on Target (DOT) 2026, a leading conference dedicated to the latest advances in drug targets and enabling technologies for therapeutic discovery. Held annually in Boston, Discovery on Target brings together scientists from pharma, biotech, and academia to explore emerging approaches for identifying and validating novel drug targets, as well
CologneVariational AI at BIO-Europe 2026
Variational AI will participate in BIO-Europe 2026, one of the world’s leading partnering conferences for the biotechnology and pharmaceutical industries. The event brings together biotech companies, pharmaceutical firms, investors, and technology innovators from across the global life sciences ecosystem to explore partnerships, licensing opportunities, and new approaches to advancing therapeutic development. Meet the Variational AI
Media & Resources
AI, Drug Discovery & Startups: A Candid Talk with Handol Kim, CEO of Variational AI
In this conversation, Handol shares how his team is rethinking drug discovery using generative AI, tackling one of the most complex and high-stakes challenges in science. From a 25-year career… Read More about AI, Drug Discovery & Startups: A Candid Talk with Handol Kim, CEO of Variational AI
How Generative AI Helped Design a Brain-Penetrant Cancer Drug Candidate (Webinar Recording)
From Handshake to Breakthrough: How Generative AI Helped Design a Brain-Penetrant Cancer Drug Candidate (Webinar Recording) In this 60-minute fireside chat, Rakovina Therapeutics and Variational AI share the story behind… Read More about How Generative AI Helped Design a Brain-Penetrant Cancer Drug Candidate (Webinar Recording)
What’s with RWE Podcast: Generative AI for Drug Discovery
Handol Kim, CEO of Variational AI, shares insights on the growing role of generative AI in pharmaceutical research. The discussion highlights how advanced machine learning approaches can help researchers explore… Read More about What’s with RWE Podcast: Generative AI for Drug Discovery
Variational AI – Emerging Company of the Year
27th Annual LSBC Award – Awards Video – Emerging Company of the Year -Biotech: Variational AI Read More about Variational AI – Emerging Company of the Year